pyrroles has been researched along with Fatty Liver in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (26.32) | 29.6817 |
| 2010's | 26 (68.42) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Dikshit, M; Gupta, SK; Jatavallabhula, SL; Kamboj, P; Kumar, A; Kumar, Y; Kumari, D; Mahajan, D; Mukhi, S; Rai, RK; Sarkar, S; Sasibhushan, V; Sharma, V | 1 |
| Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T | 1 |
| Braeuning, A; Lasch, A; Lichtenstein, D; Marx-Stoelting, P | 1 |
| Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S | 1 |
| Bochar, OM | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Moedas, AR; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Arihiro, K; Chayama, K; Hyogo, H; Inoue, M; Ishitobi, T; Iwamoto, K; Nabeshima, Y; Nonaka, M; Tazuma, S | 1 |
| Kirilmaz, A; Uzun, M; Yiğiner, O | 1 |
| Adánez, G; Ayala, I; Castells, MT; Martín-Castillo, A; Pérez, BG; Polo, MT | 1 |
| Arihiro, K; Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Nabeshima, Y; Takeuchi, M; Yamagishi, S | 1 |
| Tasci, I | 1 |
| Yilmaz, Y | 1 |
| Ahmadi, N; Budoff, MJ; Foster, T; Gordon, C; Guerci, AD; Saab, S | 1 |
| Alegret, M; Ađalsteisson, GS; Laguna, JC; Merlos, M; Rebollo, A; Roglans, N; Vilà, L | 1 |
| Caballero, F; Elena, M; Fernández, A; Fernández-Checa, JC; García-Ruiz, C; Llacuna, L; Martínez, L; Matías, N; Montfort, CV; Morales, A; Rimola, A | 1 |
| Allard, JP; Arendt, BM | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X | 1 |
| Hassanian, MA; Samy, W | 1 |
| Heger, M; Reiniers, MJ; van Golen, RF; van Gulik, TM | 1 |
| Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Maeda, S; Yamagishi, S | 1 |
| Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J | 1 |
| Lonardo, A; Loria, P | 1 |
| Gracia-Sancho, J | 1 |
| Yamagishi, S | 1 |
| Angelico, F; Del Ben, M; Pignatelli, P; Violi, F | 1 |
| Oĭnotkinova, OSh | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Hyogo, H; Maeda, S; Yamagishi, S | 1 |
| Adim, SB; Dolar, E; Gulten, M; Gurel, S; Kiyici, M; Memik, F; Nak, SG; Savci, G; Yerci, O | 1 |
| Moreno Sánchez, D | 1 |
| García-Buey, L; Gisbert, JP; Gómez-Domínguez, E; Moreno-Monteagudo, JA; Moreno-Otero, R | 1 |
| Athyros, VG; Burroughs, AK; Didangelos, TP; Elisaf, MS; Giouleme, OI; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Arcas, I; Ayala, I; Castells, MT; Corral, J; García-Pérez, B; Hernández-Espinosa, D; Martín-Castillo, A; Miñano, A; Vicente, V | 1 |
| Georgescu, EF; Georgescu, M | 1 |
| Gao, Y; Ge, GY; Jia, YJ; Jiang, MN; Song, LX | 1 |
3 review(s) available for pyrroles and Fatty Liver
| Article | Year |
|---|---|
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Topics: Chalcones; Diabetes Mellitus, Type 2; Drug Development; Fatty Liver; Humans; Hypoglycemic Agents; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pioglitazone; Propionates; Pyrroles | 2019 |
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin | 2013 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
9 trial(s) available for pyrroles and Fatty Liver
| Article | Year |
|---|---|
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides | 2014 |
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Biopsy; Body Mass Index; Dyslipidemias; Fatty Liver; Female; Follow-Up Studies; Glucose Tolerance Test; Glycation End Products, Advanced; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Reactive Oxygen Species; Tomography, X-Ray Computed; Young Adult | 2010 |
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Antioxidants; Ascorbic Acid; Atorvastatin; California; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin D | 2011 |
Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?
Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Confidence Intervals; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pyrroles; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin A | 2011 |
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides | 2011 |
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Fatty Liver; Female; Hepatitis; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Ursodeoxycholic Acid | 2003 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Orlistat; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Weight Loss | 2006 |
Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholagogues and Choleretics; Fatty Liver; Female; Hematologic Agents; Hepatitis; Heptanoic Acids; Humans; Losartan; Male; Middle Aged; Pentoxifylline; Pyrroles; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
26 other study(ies) available for pyrroles and Fatty Liver
| Article | Year |
|---|---|
Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
Topics: Animals; Cell Line; Diet; Diet, High-Fat; Fatty Liver; Fructose; Humans; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipidomics; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Phenylpropionates; Pyrroles | 2021 |
More than additive effects on liver triglyceride accumulation by combinations of steatotic and non-steatotic pesticides in HepaRG cells.
Topics: Adverse Outcome Pathways; Carcinoma, Hepatocellular; Cell Line, Tumor; Dioxolanes; Dioxoles; Fatty Acids; Fatty Liver; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Models, Theoretical; Pesticides; Pyrroles; Triazoles; Triglycerides | 2021 |
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles | 2013 |
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Fatty Liver; Heptanoic Acids; Humans; Metabolic Diseases; Non-alcoholic Fatty Liver Disease; Patient Compliance; Pyrroles; Risk; Risk Reduction Behavior | 2013 |
A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Lipids; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains | 2009 |
The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome.
Topics: Adult; Alanine Transaminase; Atorvastatin; Contraindications; Coronary Artery Disease; Fatty Liver; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Pyrroles | 2009 |
Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.
Topics: Animals; Atorvastatin; Chickens; Cholesterol; Disease Models, Animal; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2010 |
Clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Diabetes Mellitus; Fatty Liver; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2010 |
The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Fatty Liver; Glycation End Products, Advanced; Heptanoic Acids; Humans; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2010 |
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cyclic AMP-Dependent Protein Kinases; Dietary Carbohydrates; Disease Models, Animal; Down-Regulation; Fatty Acids; Fatty Liver; Fructokinases; Fructose; Gene Expression Regulation; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; I-kappa B Proteins; Inflammation Mediators; Lipid Metabolism; Liver; Male; Metallothionein; Necrosis; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides | 2011 |
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline; Choline Deficiency; Disease Models, Animal; Disease Susceptibility; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Glutathione; Heptanoic Acids; Lipotropic Agents; Liver; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Pyrroles; Quinuclidines; Reperfusion Injury | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
Topics: Animals; Atorvastatin; Combined Modality Therapy; Dietary Fats; Fatty Liver; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Organ Size; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1; Transaminases | 2011 |
2',7'-Dichlorofluorescein is not a probe for the detection of reactive oxygen and nitrogen species.
Topics: Animals; Anticholesteremic Agents; Cholesterol, Dietary; Fatty Liver; Heptanoic Acids; Male; Mevalonic Acid; Pyrroles; Reperfusion Injury | 2012 |
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Topics: Adiponectin; Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Collagen Type IV; Dyslipidemias; Fatty Liver; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Regression Analysis; Severity of Illness Index; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4 | 2012 |
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Non-alcoholic Fatty Liver Disease; Pyrroles; Tumor Necrosis Factor-alpha | 2012 |
Enhancing organ pool by statins: is this the future?
Topics: Animals; Atorvastatin; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; Toll-Like Receptor 4 | 2012 |
Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
[Specific features of hypolipidemic therapy in patients with abdominal ischemic disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cholagogues and Choleretics; Drug Therapy, Combination; Fatty Liver; Female; Heptanoic Acids; Humans; Ischemia; Male; Middle Aged; Pyrroles; Ursodeoxycholic Acid; Young Adult | 2012 |
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Author reply: comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
Topics: Anticholesteremic Agents; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Evaluation; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Intracellular retention of hepatic serpins caused by severe hyperlipidemia.
Topics: Animals; Antithrombins; Atorvastatin; Chickens; Dietary Fats; Disease Models, Animal; Factor Xa Inhibitors; Fatty Liver; Heparin Cofactor II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intracellular Fluid; Lipid Metabolism; Lipids; Liver; Male; Pyrroles; Serpins | 2006 |
Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis.
Topics: Acute-Phase Proteins; Alanine Transaminase; Animals; Atorvastatin; Carrier Proteins; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Endotoxins; Fatty Liver; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-1beta; Lipids; Lipopolysaccharide Receptors; Liver; Lymphocyte Antigen 96; Male; Membrane Glycoproteins; NF-kappa B; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Immunologic; RNA, Messenger; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2008 |